Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Top Neuroscience Partnering Opportunities: Seeking To Alter Treatment Paradigms

This article was originally published in The Pink Sheet Daily

Executive Summary

Neuroscience track at the Therapeutic Area Partnerships conferencewill feature novel candidates for Alzheimer’s, depression, traumatic brain injury, Fragile X syndrome and post-herpetic neuralgia.

You may also be interested in...

Single Positive Endpoint Enough For Prana To Move Huntington’s Candidate To Pivotal Trial

The PBT2 compound boosts executive function in first Phase II trial, but fails all other efficacy endpoints; however, past regulatory experience suggests that with few treatment options, one endpoint can do the trick in hard-to-treat Huntington’s disease.

Alzheimer’s Experts Pin Hopes On Prions, Immunology And Genetic Discoveries

Leading Alzheimer’s experts discuss the status of new therapeutic approaches based on the pathophysiology of related diseases, new gene discoveries from GWAS, the inflammatory cascade and environmental epigenetics. Surprisingly, there is still untapped promise in a-beta and tau.

AstraZeneca Opts Out Of Targacept Schizophrenia Program

Targacept says it will continue to develop its schizophrenia drug, even though AstraZeneca has opted not to move forward.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts